This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Q4 Earnings Roundup: JNJ, VZ, MMM, DD, Etc.
by Mark Vickery
Ahead of the opening bell today, we have plenty of Q4 earnings results to report.
J&J (JNJ) Q4 Earnings Top; Seeks Options for Diabetes Unit
by Zacks Equity Research
Johnson & Johnson (JNJ) reported a mixed quarter with earnings beating expectations while sales missing the same.
The Zacks Analyst Blog Highlights: Goldman Sachs, DuPont, Johnson & Johnson, Verizon Communications and Travelers Companies
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Goldman Sachs, DuPont, Johnson & Johnson, Verizon Communications and Travelers Companies
J&J (JNJ) Beats on Q4 Earnings, Sales Miss; Stock Down
by Zacks Equity Research
JNJ beat on fourth quarter earnings - the company reported EPS of $1.58 while our consensus called for EPS of $1.56.
The Best Earnings Charts on the Street
by Tracey Ryniec
It's not easy to beat on earnings every quarter for years but these companies are doing it.
Dow Stocks to Watch for Earnings on Nov 24: DD, JNJ, TRV, VZ
by Swarup Gupta
The nature of these releases is likely to determine the fortunes of the Dow in the days ahead.
Can Q4 Earnings Revitalize Healthcare ETFs?
by Sweta Killa
The Q4 earnings could bring some near-term relief given that the sector is expected to post earnings growth of 2.9% and revenue growth of 5.6%.
5 Best Performing Healthcare Mutual Funds of 2016
by Zacks Equity Research
Investors rely on the healthcare firms to safeguard their investments as demand for its services does not vary much with market conditions
J&J Arm Buys Megadyne, Boosts Electrosurgical Tools Portfolio
by Zacks Equity Research
Ethicon Endo-Surgery, Inc. a subsidiary of Johnson & Johnson (JNJ), announced the acquisition of Megadyne Medical Products, Inc., a privately held medical device company.
What's in Store for Abbott Labs (ABT) This Earnings Season?
by Zacks Equity Research
Abbott Laboratories (ABT) is scheduled to report fourth-quarter and full year 2016 results before the opening bell on Jan 25.
Abbvie (ABBV) Imbruvica Approved in Lymphoma Indication
by Zacks Equity Research
AbbVie Inc. (ABBV) announced that the FDA has approved its blood cancer drug, Imbruvica, for the treatment of patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).
What???s Ahead for Johnson & Johnson (JNJ) in Q4 Earnings?
by Zacks Equity Research
Johnson & Johnson (JNJ), the bellwether of healthcare companies, is scheduled to report fourth-quarter 2016 and full-year results on Jan 24.
Stock Market Roundup Jan. 11: Health Sector Lower on Trump "Murder" Comment
by Madeleine Johnson
After President-elect Donald Trump said pharmaceutical companies were ???getting away with murder,??? in how much they charge the government for medicines.
Novo Nordisk (NVO) Fiasp Gets EU Nod for Diabetes in Adults
by Zacks Equity Research
Novo Nordisk (NVO) announced that its fast-acting insulin aspart, Fiasp, has been approved in the EU for the treatment of diabetes in adults.
5 ETF Investment Ideas for 2017
by Neena Mishra
We have highlighted some ETF areas that are likely to shine in 2017.
Bristol-Myers, GeneCentric Tie Up for Opdivo Biomarker Study
by Zacks Equity Research
Bristol-Myers (BMY) and GeneCentric Diagnostics inked an exploratory biomarker research collaboration.
Pfizer's Humira Biosimilar Meets Primary Endpoint in Study (Revised)
by Zacks Equity Research
Pfizer, Inc. (PFE) announced positive top-line results from the comparative REFLECTIONS B538-02 study on its investigational compound, PF-06410293, a potential biosimilar to AbbVie Inc.'s (ABBV) Humira.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Barclays, Procter & Gamble, Kellogg and Medtronic
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Barclays, Procter & Gamble, Kellogg and Medtronic
Pfizer's Humira Biosimilar Meets Primary Endpoint in Study
by Zacks Equity Research
Pfizer, Inc. (PFE) announced positive top-line results from the comparative REFLECTIONS B538-02 study on its investigational compound, PF-06410293, a potential biosimilar of Humira approved for the treatment of patients with rheumatoid arthritis.
Bristol-Myers, J&J Ink Immunotherapy Research Collaboration
by Zacks Equity Research
Bristol-Myers (BMY) entered into an immunotherapy clinical research collaboration with Johnson & Johnson to evaluate a combination of Opdivo and Darzalex.
Lilly Jardiance Family Diabetes Drugs' Label to be Updated
by Zacks Equity Research
Eli Lilly & Company (LLY) recently announced that the FDA has approved the inclusion of data from the EMPA-REG OUTCOME study on the labels of three type 2 diabetes medicines belonging to the Jardiance family ??? Synjardy, Synjardy XR and Glyxambi.
Company News for January 03, 2017
by Zacks Equity Research
Companies In The News are: MYL,JNJ,GPOR,PBR,S,TMUS
Mylan (MYL) Announces Multiple Generic Launches in the U.S.
by Zacks Equity Research
Mylan (MYL) announced quite a few generic launches in the U.S. in Dec 2016.
Achillion Receives $15M from J&J for HCV Study Enrolment
by Zacks Equity Research
Achillion Pharmaceuticals, Inc. (ACHN) announced that it has received a milestone payment of $15 million from Johnson & Johnson's (JNJ) pharma wing, Janssen for the initiation of patient enrollment in the OMEGA-1 phase IIb global study of JNJ-4178.
Anthera (ANTH) Stock Falls on Poor Phase III Sollpura Data
by Zacks Equity Research
Anthera (ANTH) reported unimpressive top-line data from a phase III study on Sollpura in cystic fibrosis patients with exocrine pancreatic insufficiency.